Prices of bioscience shares turned down Tuesday, with 18stocks losing $1 or more. The AMEX Biotechnology Index fell3.14 points to 148.27.
Immune Response Corp. (NASDAQ:IMNR) was the most activebiotech stock, losing $2.50 to $18 on 798,000 shares.Preliminary Phase II data on the company's therapeutic HIVvaccine has met with some analyst skepticism.
Curative Technologies Inc. dropped $2.13 to $9.50 in heavytrading on the second day after announcing that it had receivedan FDA warning letter. The stock was down 38 cents Monday.
SyStemix Inc. (NASDAQ:STMX) closed unchanged at $29.50after reporting first-quarter earnings that included a $12.2million, or $1.44 per share, charge relating to the sale of 60percent of the company to Sandoz Ltd. The net loss was $14.7million, or $1.73 a share, vs. a loss of $1.7 million, or 33 cents,in the 1991 quarter. Revenues were $76,000 compared with$605,000 in the year-ago period. MEDCLONE DEAL FOR UCLAMABS
MedClone Inc. on Monday said has entered into an exclusiveworldwide licensing agreement with the University ofCalifornia that gives the Los Angeles-based biopharmaceuticalcompany commercial rights to certain monoclonal antibodies.
The antibodies, developed by Dr. Richard Weisbart, chief ofrheumatology at the UCLA San Fernando Valley Program, maybe useful in the treatment of certain human autoimmunediseases, including rheumatoid arthritis and lupus nephritis,the company said.
MedClone plans to file in the second half of the year to begintrials of its first product, MAb 3E10, a vaccine-therapy forlupus nephritis, a kidney disorder
(c) 1997 American Health Consultants. All rights reserved.